GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (OTCPK:IDRSF) » Definitions » Debt-to-Equity

Idorsia (Idorsia) Debt-to-Equity : -1.45 (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Debt-to-Equity?

Idorsia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $229.0 Mil. Idorsia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1,110.8 Mil. Idorsia's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-923.7 Mil. Idorsia's debt to equity for the quarter that ended in Sep. 2023 was -1.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Idorsia's Debt-to-Equity or its related term are showing as below:

IDRSF' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.93   Med: 0.73   Max: 11.17
Current: -1.45

During the past 7 years, the highest Debt-to-Equity Ratio of Idorsia was 11.17. The lowest was -9.93. And the median was 0.73.

IDRSF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs IDRSF: -1.45

Idorsia Debt-to-Equity Historical Data

The historical data trend for Idorsia's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Debt-to-Equity Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial 0.86 3.66 1.09 11.17 -1.86

Idorsia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -1.86 -1.42 -1.19 -1.45

Competitive Comparison of Idorsia's Debt-to-Equity

For the Biotechnology subindustry, Idorsia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Idorsia's Debt-to-Equity falls into.


Idorsia Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Idorsia's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.576 + 1307.893) / -709.487
=-1.86

Idorsia's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(229 + 1110.834) / -923.745
=-1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia  (OTCPK:IDRSF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Idorsia Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Idorsia's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia (Idorsia) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (OTCPK:IDRSF) » Definitions » Debt-to-Equity
Comparable Companies
XSWX:XLS XSWX:BSLN XSWX:SANN XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IDIAz:UK 0RQE:UK IDIA:Switzerland
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Website
https://www.idorsia.com
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.